Compare Moderna, Inc. (MRNA) vs Packaging Corporation of America (PKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Packaging Corporation of America — how do they compare? Moderna, Inc. trades at $195.7 (market cap $78.44B), while Packaging Corporation of America trades at $231.22 (market cap $20.25B). The key difference: Moderna, Inc. is far larger — about 3.9× Packaging Corporation of America's market cap, and Packaging Corporation of America pays a 2.64% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Packaging Corporation of America for 45 Days on average.
| MRNA | PKG | |
|---|---|---|
Market Cap | $78.44B | $20.25B |
Volume | 14,597,511 | 491,102 |
Sector | Health | Consumer Cyclical |
52-Week High | $203.46 | $257.43 |
52-Week Low | $22.36 | $191.68 |
Typical Hold Time | 59 Days | 45 Days |
Enterprise Value | $74.59B | $24.06B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.
Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.
Packaging Corporation of America (PKG) trades at $227.25, down 1.08% with bearish technical signals despite recent earnings beats. The company maintains solid fundamentals with $9.5B revenue projection for 2026 and 7.25% net margin, though facing margin compression from cost pressures. Recent institutional buying by BlackRock and Bank of New York Mellon contrasts with mixed analyst ratings.
PKG offers steady packaging demand exposure but faces headwinds from rising input costs and competitive pressures. The 19.8% upside to consensus price target of $272.43 presents opportunity, though investors should monitor Q3 2026 earnings results on October 22 for margin trajectory confirmation amid bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →
